Debra Liebert

Ms. Liebert joined Domain in 2007 to create new portfolio companies and evaluate the technical and business merits of investment opportunities. Improving healthcare through the development of drugs has been a focus of her 30+ year career, which included operating roles in several Domain-funded companies. She became a Principal at Domain in 2009 and Managing Director in 2014. Ms. Liebert was an observer on the boards of Atara Biotherapeutics (ATRA) and Tobira Therapeutics (TBRA). She contributed to the creation of Calixa Therapeutics, Sonexa Therapeutics and multiple seed companies.

Prior to Domain, Ms. Liebert provided development and business consulting services to the biotech and pharmaceutical industries. She also served as Executive Director of New Product Management for CancerVax Corporation where she designed and implemented development plans for pipeline product candidates. Prior to CancerVax, Ms. Liebert held the position of Vice President, Corporate Development at Atairgin Technologies, where she led product and business development, and at Trega Biosciences, where she led corporate development transactions including merger of the company. Ms. Liebert also directed clinical research programs for Gensia, the Institute for Biological Research and Development, and Merck & Co. Ms. Liebert has served on Milestone’s Board of Directors since 2015.

Ms. Liebert received her B.S. in chemistry from Clarion University, her M.S. in pharmacology/toxicology from Duquesne University, and her MBA from University of California, Los Angeles.